A lack of uniformity exists for insurance payer coverage for all categories of penile prostheses (PP). We sought to determine common insurance coverage criteria and barriers to implantation across common insurance plans from healthcare referral regions (HRR) nationwide. Coverage criteria and stipulations were reviewed regarding erectile dysfunction (ED) etiology, ED duration, contributing comorbid conditions, medications, drug use, diagnostic tests, use of procedures and prior interventions. Seventy of 100 plans included coverage criteria. 36.1% provided coverage only in cases of gender dysphoria. 27.7% required documentation of trial, contraindication or intolerance to pharmacologic therapy, with varying descriptors of what this entailed. 13.8% required at least consideration of prior pharmacologic therapy. 4.2% required trial or contraindication to classic second-line therapies. 25.0% stated that ED must be organic. Psychogenic ED was covered by 12.5% of plans. Eleven plans required at least 6 or 12 months of symptoms. Laboratory evaluation to rule out hypogonadism or hyperprolactinemia was required by five plans. Insurance coverage criteria for PP placement were highly variable by state and plan. Coverage is provided for PP implantation in most cases for ED of organic etiology following failure of pharmacologic therapy when contributing comorbidities are optimally managed.

对于所有类别的阴茎假体 (PP)，保险支付人的承保范围缺乏统一性。我们试图确定来自全国医疗转诊地区 (HRR) 的共同保险计划的共同保险覆盖标准和植入障碍。审查了有关勃起功能障碍 (ED) 病因、ED 持续时间、促成合并症、药物、药物使用、诊断测试、程序使用和先前干预措施的覆盖标准和规定。100 个计划中有 70 个包含覆盖标准。36.1% 仅在性别不安的情况下提供保险。27.7% 需要对药物治疗进行试验、禁忌症或不耐受的文件，并有不同的描述。13.8% 至少需要考虑先前的药物治疗。4. 2% 需要对经典二线疗法进行试验或禁忌。25.0% 表示 ED 必须是有机的。12.5% 的计划涵盖心因性 ED。十一项计划需要至少 6 或 12 个月的症状。五个计划要求进行实验室评估以排除性腺机能减退或高催乳素血症。PP 安置的保险范围标准因州和计划而异。在大多数情况下，在药物治疗失败后的器质性 ED 的情况下，当促成合并症得到最佳管理时，为 PP 植入提供了保障。PP 安置的保险范围标准因州和计划而异。在大多数情况下，在药物治疗失败后的器质性 ED 的情况下，当促成合并症得到最佳管理时，为 PP 植入提供了保障。PP 安置的保险范围标准因州和计划而异。在大多数情况下，在药物治疗失败后的器质性 ED 的情况下，当促成合并症得到最佳管理时，为 PP 植入提供了保障。